Valion Bio, Inc. (TIVC) 股票分析

公司概述

Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company focused on developing therapeutic solutions for critical medical conditions. The firm functions within the Healthcare sector, specifically specializing in the Medical Devices industry, which implies a focus on innovative tools and biological treatments rather than standard consumer goods. The company's market capitalization stands at $2.96M, with an employee count of 52, reflecting a small-cap profile typical of early-to-mid stage biotechnology entities. The combination of a sub-$3 million market cap and a relatively small workforce indicates that Tivic Health Systems is a micro-cap entity with limited operational scale, positioning it as a high-risk, high-potential venture heavily reliant on the successful development of its lead drug candidate, Entolimod, rather than established commercial revenue streams.

财务健康

The company reports a Net Income (TTM) of $-7,993,000 and an EBITDA of $-7,893,000, while Revenue (TTM) is listed as N/A, suggesting that the firm is not yet generating significant commercial sales or is in a pre-revenue phase where revenue recognition differs from standard operational metrics. The substantial negative gap between revenue and net income, alongside the absence of reported revenue, reveals a cost structure dominated by research and development expenses typical of late-stage immunotherapeutics companies. Free Cash Flow is recorded at $-4,292,500, indicating that the company is consuming cash reserves to fund its pipeline, which limits immediate financial flexibility but is consistent with the burn rate required for late-stage drug development. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, which indicates that the company has not yet achieved commercial profitability or is operating under accounting methods that defer revenue recognition until product approval. Regarding liquidity and leverage, the company holds $12.64M in cash against $6.45M in debt, resulting in a Debt to Equity ratio of 38.42, which suggests a capital structure where debt constitutes a significant portion of equity, though the cash position provides a buffer against near-term obligations. The Current Ratio stands at 20.13, a figure that indicates exceptional short-term liquidity relative to current liabilities, allowing the firm to comfortably meet its immediate financial obligations without distress. Return on Equity is -82.7% and Return on Assets is -28.7%, metrics that reveal that management is currently unable to generate positive returns on the capital invested, a common characteristic of companies in deep development phases prior to market entry.

估值评估

The company's Trailing P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed as -0.04, a valuation metric that implies the market expects earnings to remain negative or is pricing the stock based on non-traditional metrics given the lack of positive profit history. The Price to Book ratio is 0.15, indicating that the market values the company at significantly less than its net asset value, which often occurs with speculative biotech firms where the asset base is undervalued on a traditional accounting basis. The Price to Sales ratio is N/A and the EV/EBITDA is 0.41, suggesting that alternative valuation methods relying on revenue multiples are not applicable due to lack of sales, while the low EV/EBITDA multiple reflects the company's negative earnings and high-risk profile. The stock's 52-Week High is $13.23 and the 52-Week Low is $0.72, providing a trading range of approximately 1845% that highlights the extreme volatility inherent in small-cap immunotherapeutics stocks. Although the specific current price is not explicitly provided in the facts, the 52-week range demonstrates that the asset has experienced massive price swings, potentially trading at various percentages above the $0.72 low or below the $13.23 high depending on market conditions at any given moment. The Beta value is 1.84, which indicates that the stock's price volatility is substantially higher than the broader market, moving with an amplified intensity that exposes investors to greater risk during market downturns.

Growth & Income

Revenue Growth (YoY) and Earnings Growth (YoY) are both listed as N/A, reflecting the company's status as a pre-commercial entity where historical growth rates are not yet established or relevant for traditional analysis. Because the growth metrics are unavailable, it is impossible to determine whether earnings are growing faster or slower than revenue, as the primary metric for commercial scaling is currently absent from the financial statements. The company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the firm reinvests all available resources and any remaining cash flow directly back into research and development rather than distributing income to shareholders. This reinvestment strategy is standard for late-stage immunotherapeutics companies that must prioritize clinical trial completion and regulatory approval over shareholder income distributions. Consequently, the overall growth and income profile is characterized by a total reliance on capital preservation and pipeline advancement, with no current income generation or historical growth trajectory to analyze against market benchmarks.